Condition: Wilms Tumor · Sponsor: Centre Oscar Lambret
This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.
This description comes directly from the study's public registry record.
Emilie Heyman - Decoupigny · +33 (0)3 20 29 59 18 · promotion@o-lambret.fr
Marie Vanseymortier · +33 (0)3 20 29 59 18 · promotion@o-lambret.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens Picardie | Amiens, France | Not Yet Recruiting |
| CHU de Besancon | Besançon, France | Recruiting |
| CHRU de Bordeaux Hôpital des Enfants | Bordeaux, France | Recruiting |
| CHU GRENOBLE ALPES - Hôpital COUPLE ENFANT | Grenoble, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Hôpital pour Enfants " La Timone " AP-HM | Marseille, France | Recruiting |
| CHU de MONTPELLIER - Hôpital Arnaud de Villeneuve | Montpellier, France | Not Yet Recruiting |
| CHU Nantes | Nantes, France | Recruiting |
| CHU de Nice - Hôpital Archet 2 | Nice, France | Recruiting |
| Hôpital Armand-TROUSSEAU | Paris, France | Recruiting |
| CHU Hôpital Sud | Rennes, France | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05384821